Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review
- First Online:
- 335 Downloads
This retrospective study compared renal impairment rates in breast cancer, multiple myeloma, prostate cancer and non-small cell lung cancer patients treated with ibandronate or zoledronic acid.
Medical records in two German oncology clinics from May 2001 to March 2006 were retrospectively reviewed. Creatinine measurements were analyzed from baseline (before bisphosphonate treatment) to last available measurement for each patient. The Cox proportional hazards model and the Andersen–Gill extension of the Cox model for multiple events analysis were used for multivariate analysis, which controlled for age, clinic site, primary cancer type, baseline SCr or GFR value, prior bisphosphonate use, concomitant use of drugs associated with acute renal failure, and renal-related comorbidities.
Of 333 patients, 109 received ibandronate and 256 received zoledronic acid (32 patients had both drugs). Compared with ibandronate, the zoledronic acid group had a significantly better baseline renal function and fewer patients had a history of renal disease. Zoledronic acid treatment increased the relative risk (RR) and the incidence rate (IR) of renal impairment by ~1.5-fold in all assessed patients (all tumors) compared with ibandronate. Multivariate analysis found significantly higher hazards ratios for zoledronic acid over ibandronate (two to sixfold), after adjusting for differences in characteristics between the two treatment groups.
In this retrospective review, patients were significantly more likely to experience renal impairment with zoledronic acid than with ibandronate.
KeywordsZoledronic acid Ibandronate Renal impairment Medical records Creatinine clearance
- 6.Body JJ, Lichinitser M, Tjulandin S, Bergström B (2006) Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data [abstract 68]. Bone 38(3 Suppl.1):S69Google Scholar
- 10.Diel IJ, Weide R, Köppler H et al (2006) Renal impairment in cancer patients following zoledronic acid or ibandronate treatment [abstract 1002P]. Ann Oncol 17(Suppl.9):78Google Scholar
- 11.Eastell R, Garnero P, Vrijens B et al (2006) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408Google Scholar
- 14.Heidenreich A, Ohlmann C, Olbert P Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl.5):S270Google Scholar
- 16.Johnson KB, Gable P, Kaine EM et al (2003) Significant deterioration in renal function with the new bisphosphonate zoledronic acid [abstract 2968]. J Clin Oncol 22(Suppl.):738Google Scholar
- 23.Mazj S, Lichtman SM (2004) Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics [abstract 8039]. J Clin Oncol 22(Suppl.):735Google Scholar
- 29.Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744PubMedCrossRefGoogle Scholar
- 32.von Moos R, Caspar CB, Angst R et al (2006) Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [abstract 1078]Google Scholar